GPSC
MAR 0 4 1999

Molecular medicine today

Author Index

Subject Index

Books Reviewed

1998

Vol 4
Issues 1–12

ISSN 1357 4329

Molecular Medicine Today

Elsevier Trends Journals
68 Hills Road
Cambridge
UK CB2 1LA
Tel: +44 1223 315961
Fax: +44 1223 464430
+44 1223 321410
e-mail: mmt.trends@elsevier.co.uk

Advisory Editorial Board S. Agrawal, Cambridge, USA
P. Berg, Stanford, USA
H. Blau, Stanford, USA
T. Blundell, Cambridge, UK
D. Choi, St Louis, USA
T. Cox, Cambridge, UK
K. Culver, Gaithersburg, USA
K. Davies, Oxford, UK
I. Dunham, Hinxton, UK
R. Flavell, New Haven, USA
D. Gordon, London, UK
W. Günzburg, Vienna, Austria
J.M. Leiden, Chicago, USA
M.A. Liu, West Point, USA
K. Matsushima, Tokyo, Japan
A. McMichael, Oxford, UK
M. Noble, Salt Lake City, USA
W. Petri, Charlottesville, USA
B. Ponder, Cambridge, UK
D. Prockop, Philadelphia, USA
Z. Ram, Tel-Hashomer, Israel
T. Soussi, Paris, France
L-C. Tsui, Toronto, Canada
D. Young, London, UK
H. zur Hausen, Heidelberg, Germany

Editor Catherine Brooksbank

Editorial Administrators Sandra Taylor, Alan Sloan and Anne Ward

Assistant Editor Jane Alfred

Editorial Assistant Helen Carroll

Publisher Peter Desmond

© 1999 Elsevier Science Ltd. All rights reserved.

This journal and the individual contributions contained in it are protected by the copyright of Elsevier Science Ltd. Except as outlined in the terms and conditions, no part of this publication may be reproduced, stored in a retrieval system or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, without the prior written permission of the publisher, Elsevier Trends Journals, 68 Hills Road, Cambridge, UK CB2 1LA.

AUTHOR INDEX

Abbreviations: (B), Books; (C), Letters; (E), Editorial; (L), Literature; (M), Meetings; (N), News; (O), Opinion; (P), Perspectives

A

Abdulla, S., Alcohol: friend or foe to the cardiovascular system? (M) 9
Abdulla, S., Getting to the heart of gap junction pathology (M) 192
Abdulla, S., Noise-induced hearing loss: the future is hear (M) 284
Abdulla, S., Tuberculosis: milking the genome for drug targets and vaccines (M) 104
Agranov, G., see Lazarov-Spiegler, O. 337
Agrawal, B., Gendler, S.J. and Longenecker, B.M., The biological role of mucins in cellular interactions and immune regulation: prospects for cancer immunotherapy 397
Alberti, S., Distinguishing ulcerative colitis from autoimmunity (L) 188
Aldred, M.A., Electronic zoo blotting identifies a modifier gene for spinal muscular atropy (L) 463
Aldred, M.A., Modifying genes and retinitis pigmentosa (L) 53
Aldred, M.A., Shedding light on eye development (L) 372
Aldred, M.A., Therapy for CAG-repeat diseases (L) 187
Ali, A., see Vaira, D. 237
Alton, E.W.F.W., see Davies, J.C. 381
Alton, E.W.F.W., see Davies, J.C. 292
Amor, S., Layward, L. and van Noort, J.M., Multiple sclerosis: modelling the future (M) 328
Andrews, T.C. and Brooks, D.J., Advances in the understanding of early Huntington's disease using the functional imaging techniques of PET and SPET 532
Ash, S., see Karpas, A. 244
Ashall, F., see Ray, W.J. 151
Ashenden, L-M.A., see During, M.J. 485
Augustus, M., *Human Cytogenetic Cancer Markers* (B) 100

B

Bainbridge, D., see Karpas, A. 244
Baldini, A., see Lindsay, E.A. 350
Barnard, N.J., see Lutzker, S.G. 404
Barnes, P.J. and Lim, S., Inhibitory cytokines in asthma 452
Bishop, J.E., Regulation of cardiovascular collagen deposition by mechanical forces 69
Bonn, D., Collagen scaffold shows promise for regenerating torn knee cartilage (N) 96
Bonn, D., Commensal bacteria armed against biological warfare (N) 367
Bonn, D., Diagnosing weight disorders by measuring uncoupling proteins (N) 185
Bonn, D., Leukocyte depletion for leukaemia and multiple sclerosis (N) 508
Bonn, D., Mouse model sheds light on malnutrition in Down syndrome (N) 414
Bonn, D., New strategies to combat fungal infections (N) 50
Bonn, D., Protease inhibitors on trial for inflammatory bowel disease (N) 461
Bonn, D., Rapid diagnosis of equivocal appendicitis (N) 369
Bonn, D., Taking the p... therapeutic proteins from urine (N) 230
Bonn, D., Targeted immunosuppressant on trial for rheumatoid arthritis (N) 277
Bowles, N.E., see Wang, Q. 382
Brooksbank, C., 1998: year of the mouse? (E) 1
Brooksbank, C., A taste of the zeitgeist (M) 240
Brooksbank, C., Divide and conquer: understanding the natural history of cancer (M) 422
Brooksbank, C., Molecular medicine through the kaleidoscope (M) 146
Brooksbank, C., The new cardiology (M) 191
Brooksbank, R.A., A candidate gene for schizophrenia and bipolar disorder (L) 189
Brooksbank, R.A., The genetics of susceptibility to insulin-dependent diabetes: where are we now? (L) 417
Brophy, S., see Senior, K. 416
Buchwald, M., see Carreau, M. 201
Buckle, A-M., Immunodeficiency in chronic lymphocytic leukaemia – clues from CD154 (L) 7
Bui, T-H., see Jones, D.R.E. 10
Bustin, S.A. and Dorudi, S., Molecular assessment of tumour stage and disease recurrence using PCR-based assays 389
Bustin, S.A., Crosstalk among cancer signalling pathways (L) 511
Bustin, S.A., A new type of tumour suppressor gene: a serine/threonine kinase joins the list (L) 97
Bustin, S.A., Blocking angiogenesis disarms invasive tumours (L) 52
Bustin, S.A., Combining strategies to combat solid tumours (L) 371

C

Cameron, D.F., see Willing, A.E. 471
Campbell, L.A., see Kuo, C.C. 426
Caplen, N.J., Gene therapy: different strategies for different applications (M) 373
Caplen, N.J., Visualizing lipoplexes (L) 370
Caplen, N.J., TP53 on trial for cancer gene therapy (L) 465
Caplen, N.J., Lentiviral vectors: Aids for gene therapy (L) 51
Caplen, N.J., Mending mutations by *in vivo* site-directed mutagenesis (L) 188
Carreau, M. and Buchwald, M., Fanconi's anaemia: what have we learned from the genes so far? (R) 201
Caulfield, T., Reply to Ian Dunham (C) 336
Caulfield, T., The commercialization of human genetics: profits and problems (P) 148
Cawston, T., Matrix metalloproteinases and TIMPs: properties and implications for the rheumatic diseases 130
Cerottini, J-C., see Romero, P. 305
Chang, T.M.S. and Prakash, S., Therapeutic uses of microencapsulated genetically engineered cells 221

Chatenoud, L., Tolerogenic antibodies and fusion proteins to prevent graft rejection and treat autoimmunity 25
Chavany, C. and Jendoubi, M., Biology and potential strategies for the treatment of G_{M2} gangliosidoses 158
Clifton-Bligh, R.J., *Landmarks in Gene Regulation* (B) 236
Clifton-Bligh, R.J., *Endocrinology: Basic and Clinical Principles* (B) 12
Coffey, A., A new type of gene associated with hereditary deafness? (L) 52
Cole-Strauss, A., see Ye, S. 431
Collombet, J-M. and Coutelle, C., Towards gene therapy of mitochondrial disorders 31
Cooper, D.K.C., see Lanza, R.P. 39
Coutelle, C., see Collombet, J-M. 31

D

Davies, J.C., Geddes, D.M. and Alton, E.W.F.W., Prospects for gene therapy for cystic fibrosis: Erratum 381
Davies, J.C., Geddes, D.M. and Alton, E.W.F.W., Prospects for gene therapy for cystic fibrosis 292
de Villiers, W., Increasing the options for inflammatory bowel disease treatment? (L) 419
Diaz, R.M., see Vile, R.G. 84
Dorrell, S., Early warning cancer tests in development (N) 324
Dorrell, S., Muscling in on atherosclerosis (N) 460
Dorrell, S., New markers for cardiovascular disease (N) 415
Dorrell, S., Restoring interleukin 2 production in AIDS patients (N) 508
Dorrell, S., Selecting antibodies that block the HIV-1 coreceptor (N) 507
Dorrell, S., Towards the biosynthesis of an alternative to Taxol (N) 460
Dorudi, S., see Bustin, S.A. 389
Douglas, J.T., *Concepts in Gene Therapy* (B) 190
Dukepoo, F.C., The trouble with the human genome diversity project (C) 242
Dunham, I., Data disclosure in the Human Genome Project (C) 335
During, M.J. and Ashenden, L-M.A., Towards gene therapy for the central nervous system 485

E

Evans, K.L., An SH2 domain stands between infectious mononucleosis and a fatal lymphoproliferative disease (L) 510
Evans, K.L., Channelopathies: epilepsy joins the list (L) 417
Evans, K.L., Is too much stress bad for your brain? (L) 326
Evans, K.L., Ribozymes to the rescue? (L) 233
Exley, C., Does antiperspirant use increase the risk of aluminium-related disease, including Alzheimer's disease? (O) 107

F

Featherstone, C., Localized delivery of anti-cancer drugs by electroporation (N) 47
Feunteun, J., Breast cancer and genetic instability: the molecules behind the scenes 263
Ficazzola, M.A. and Taneja, S.S., Prospects for gene therapy in human prostate cancer 494
Frank, B., see Ye, S. 431
Freeman, T., *Differential Display Methods and Protocols* (B) 12
Fricker, J., A noninvasive prognostic indicator for bladder cancer (N) 506
Fricker, J., An ischaemic switch for gene therapy vectors (N) 183
Fricker, J., Combining strategies to improve non-viral vectors (N) 323
Fricker, J., Elastase inhibitor for detection and treatment of inflammation and infection (N) 5
Fricker, J., Hookworm anticoagulant safe in humans (N) 4
Fricker, J., Keratinocyte growth factor on trial for wound repair (N) 229
Fricker, J., Say NO to anal fissures (N) 94
Fricker, J., Tolerizing B cells to jump the first hurdle in xenotransplantation (N) 462
Fricker, J., Triplex DNA as a novel diagnostic tool (N) 140
Fricker, J., Tuning into plasma lipoproteins (N) 413

G

Galle, P.R., see Strand, S. 63
Gargus, J.J., Fantino, E. and Gutman, G.A., A piece in the puzzle: an ion channel candidate gene for schizophrenia (O) 518
Geddes, D.M., see Davies, J.C. 381
Geddes, D.M., see Davies, J.C. 292
Gendler, S.J., see Agrawal, B. 397
Giles, R.H., Unshrouding the human genome (M) 238
Giles, R.H., Unshrouding the human genome: Erratum 312
Gleadle, J.M. and Ratcliffe, P.J., Hypoxia and the regulation of gene expression 122
Goate, A.M., see Ray, W.J. 151
Gordon, J.W., Germline alteration by gene therapy: assessing and reducing the risks (O) 468
Günzburg, W.H., *Retroviruses* (B) 283
Gurwitz, D. and Kloog, Y., Do endogenous cannabinoids contribute to HIV-mediated immune failure? (O) 196
Gurwitz, D., A new handle on Alzheimer's amyloid toxicity (L) 7
Gurwitz, D., Haemorrhagic shock: endogenous cannabinoids to the rescue (L) 99
Gurwitz, D., New evidence for neuroprotection by estrogen (L) 281
Gurwitz, D., Non-viral gene transfer: liposomes and nanospheres promise to deliver the goods (L) 464
Gurwitz, D., Oxidative stress in Parkinson's disease: clues for new therapeutic directions (L) 371
Gurwitz, D., Uric acid may herald new hopes for multiple sclerosis patients (L) 144

H

Hata, A., Shi, Y. and Massagué, J., TGF-β signalling and cancer: structural and functional consequences of mutations in Smads 257
Hawthorne, M.F., New horizons for therapy based on the boron neutron capture reaction 174
Heuertz, R.M., *Proinflammatory and Antiinflammatory Peptides* (B) 375
Hewitt, C.R.A., Attraction and the single cell (L) 187
Hewson, R., Asymmetric release explains rotavirus pathogenesis (L) 6
Hewson, R., Borna disease virus takes the acid test (L) 142
Hewson, R., Retroviruses and xenotransplantation: determining the risks (L) 280
Hewson, R., Turning off the TAP: how HSV inhibits antigen presentation (L) 8
Hingorani, A.D., *Protein Dysfunction in Human Genetic Disease* (B) 517
Hoffman, E.P., see van Deutekom, J.C.T. 214
Huard, J., see van Deutekom, J.C.T. 214

I

Issa, J-P., see Lengauer, C. 102
Ivanov, E., Aspirin as a cancer-preventing drug (L) 510
Ivanov, E., Protein engineering for the chemotherapy of cancer (L) 233

J

Jack, D., Do efflux pumps hold the key to better antifungal treatment? (N) 275
Jakes, R., see Riess, O. 438
Jendoubi, M., see Chavany, C. 158

Jones, D.R.E. and Bui, T-H., Fetal therapy: prospects for transplantation early in pregnancy (M) 10

K

Kaplan, G., Tuberculosis research comes of age (M) 330
Karpas, A., Ash, S. and Bainbridge, D., How to prolong the effects of combination therapy for HIV (O) 244
Kill, I.R., Ageing research in the UK: plenty of proliferative potential (M) 466
Kilpatrick, M.W. and Phylactou, L.A., Towards an RNA-based therapy for Marfan syndrome 376
Kimchi, A., see Kissil, J.L. 268
Kirchhausen, T., Wiskott–Aldrich syndrome: a gene, a multi-functional protein, and the beginnings of an explanation 300
Kissil, J.L. and Kimchi, A., Death-associated proteins: from gene identification to the analysis of their apoptotic and tumor suppressive functions 268
Kloog, Y., see Gurwitz, D. 196
Kmiec, E.B., see Ye, S. 431
Kosik, K.S., *Alzheimer Disease: From Molecular Biology to Therapy* (B) 58
Krüger, R., see Riess, O. 438
Kubbutat, M.H.G. and Vousden, K.H., Keeping an old friend under control: regulation of p53 stability 250
Kuo, C.C. and Campbell, L.A., Is infection with *Chlamydia pneumoniae* a causative agent in atherosclerosis? (O) 426

L

Lanza, R.P. and Cooper, D.K.C., Xenotransplantation of cells and tissues: application to a range of diseases, from diabetes to Alzheimer's 39
Layward, L., see Amor, S. 328
Lazarov-Spiegler, O., Rapalino, O., Agranov, G. and Schwartz, M., Restricted inflammatory reaction in the CNS: a key impediment to regeneration (O) 337
Lengauer, C. and Issa, J-P., The role of epigenetics in cancer (M) 102
Lim, S., see Barnes, P.J. 452
Lindsay, E.A. and Baldini, A., Congenital heart defects and 22q11 deletions: which genes count? 350
Lindsay, J.A., Close encounters of the type III secretion kind (L) 233
Lindsay, J.A., Virulence at the flick of a switch (L) 370
Lindsay, J.A., Keeping antibacterials inside bacteria (L) 465
Lindsay, J.A., Uropathogenic *E-coli* use tRNA to regulate one of their virulence factors (L) 6
Lindsay, J.A., Vaccine evasion by pneumococci: as easy as changing a cassette (L) 99
Longenecker, B.M., see Agrawal, B. 397
López-Larrea, C., González, S. and Martínez-Borra, J., The role of HLA-B27 polymorphism and molecular mimicry in spondylarthropathy 540
Lutzker, S.G. and Barnard, N.J., Testicular germ cell tumors: molecular understanding and clinical implications 404

M

MacDonald, C., Animal cell technology for new healthcare products (M) 54
Mariani, B.D. and Tuan, R.S., Advances in the diagnosis of infection in prosthetic joint implants (R) 207
Marks, J., The trouble with the human genome diversity project (C) 243
Martin, G.M. and Wang, E., Aging and longevity: towards the next millennium (M) 145
Massagué, J., see Hata, A. 257
McKay, I.A., New thyroid hormone: kept in shape to help you lose weight (L) 370
McKay, I.A., NF-IL6 as a retinoid target in psoriasis (L) 234
McKay, I.A., Systematic synthesis of nonviral gene therapy vectors (L) 418
McKay, I.A., Winning the war against antibiotic resistance (L) 281
Mierke, D.F., Therapeutic approaches for sticky situations (M) 194
Ming, J.E., Roessler, E. and Muenke, M., Human developmental disorders and the sonic hedgehog pathway 343
Morison, I.M. and Reeve, A.E., Insulin-like growth factor 2 and overgrowth: molecular biology and clinical implications 110
Morris, J.A. and Carstea, E.D., Niemann–Pick C disease: cholesterol handling gone awry 525
Morriss-Kay, G.M., *Molecular Genetics of Early Human Development* (B) 420
Mörtl, M.G., see Widschwendter, M. 286
Mousa, S.A., *Regulation of Angiogenesis* (B) 101
Mueller, W., *Cytokine Knockouts* (B) 282
Muenke, M., see Ming, J.E. 343
Munford, R.S., see Varley, A.W. 445

N

Nichter, L.S., see Tuan, T-L. 19
Nickoloff, B.J., Pathogenesis and immunointervention strategies for psoriasis (M) 512
Normanno, N. and Agrawal, S., New molecular targets for anticancer therapy (M) 514
Novelli, G., Baldness as a mendelian genetic trait (L) 143

O

Osborne, L., Making an impression on X-linked mental retardation (L) 511
Osborne, L., Stretching the boundaries of elastin function (L) 325

P

Palmer, M.S., Amyloid and protein kinase C in Alzheimer's disease (L) 279
Palmer, M.S., Better mutation detection (L) 142
Palmer, M.S., New targets for regulating cholesterol (L) 51
Palmer, M.S., Splicing out dystrophin mutations (L) 419
Papavassiliou, A.G., Transcription-factor-modulating agents: precision and selectivity in drug design 358
Phylactou, L.A., see Kilpatrick, M.W. 376
Povey, S., see Young, J. 313
Prakash, S., see Chang, T.M.S. 221
Przepiorka, D. and Srivastava, P.K., Heat shock protein–peptide complexes as immunotherapy for human cancer 478

R

Ramsay, M., Analysis of fetal cells in maternal blood not yet a routine diagnostic test (L) 7
Ramsay, M., Different causes for true hermaphroditism (L) 143
Ramsay, M., p53 allele predisposes to human papillomavirus-associated cancer (L) 325
Ramsay, M., The genomics era is upon us (L) 235
Ramsay, M., Unusual imprinting defects with low recurrence risks (L) 464
Rapalino, O., see Lazarov-Spiegler, O. 337
Ratcliffe, P.J., see Gleadle, J.M. 122
Ray, W.J., Ashall, F. and Goate, A.M., Molecular pathogenesis of sporadic and familial forms of Alzheimer's disease 151
Reeve, A.E., see Morison, I.M. 110
Restifo, N.P., Cancer Vaccines '98: a reductionist approach (M) 327
Ribeiro, C., Keeping the public informed about science – lessons from the Swiss Gene Protection Initiative (C) 14
Riess, O., Jakes, R. and Krüger, R., Genetic dissection of familial Parkinson's disease 438
Roessler, E., see Ming, J.E. 343
Romero, P., Cerottini, J-C. and Waanders, G.A., Novel methods to monitor antigen-specific cytotoxic T-cell responses in cancer immunotherapy 305

S
Sachs, D.H., Brushing up on immunological tolerance (M) 105
Sanberg, P.R., see Willing, A.E. 471
Sansom, C., A new gene Web site for all (N) 509
Sansom, C., Alzheimer's research in eastern Europe benefits from US funding (N) 368
Sansom, C., Cost-effective carbohydrate synthesis permits large-scale production of an anti-inflammatory drug (N) 322
Schröcksnadel, H., see Widschwendter, M. 286
Schwartz, M., see Lazarov-Spiegler, O. 337
Senior, K. and Brophy, S., A light at the end of the tunnel for psoriasis sufferers? (N) 416
Senior, K., 'Nano dumpling' with drug delivery potential (N) 321
Senior, K., A molecular basis for sudden infant death syndrome (N) 49
Senior, K., Blood substitute receives FDA approval for veterinary use (N) 139
Senior, K., Going FISHing with peptide–nucleic acid (N) 231
Senior, K., *In utero* gene therapy: one step closer to reality (N) 505
Senior, K., Maori family initiates successful search for stomach cancer gene (N) 276
Senior, K., New US Cancer Genetics Network announced (N) 459
Shaw, D., *Essential Medical Genetics* (B) 333
Shi, Y., see Hata, A. 257
Snider, B.J., Toxic triplets provide clues to neurodegeneration (L) 280
Snider, B.J., CNS transplants make the connection (L) 98
Srivastava, P.K., see Przepiorka, D. 478
Stagg, A.J., Cancer vaccines based on dendritic cell fusions (L) 418
Stagg, A.J., Vaccines against *Chlamydia*: approaches and progress 166
Stewart, A., 'Biofilm' bacteria in chronic middle ear infection? (N) 141
Stewart, A., Baboons provide clues to osteoporosis (N) 3
Stewart, A., Dynamic molecular combing: a 'low tech' method for genetic mapping and diagnosis (N) 2
Stewart, A., Orally activated protein therapy heads towards clinical trials (N) 95
Stewart, A., Yeast arrays join the search for specific drugs (N) 48
Strand, S. and Galle, P.R., Immune evasion by tumours: involvement of the CD95 (APO-1/Fas) system and its clinical implications 63
Sunassee, K., see Vile, R.G. 84

T
Taneja, S.S., see Ficazzola, M.A. 494
Tang, Y.W. and Tau, K.R, *Molecular Diagnosis of Infectious Diseases* (B) 334
Tarkowski, A. and Wagner, H., Arthritis and sepsis caused by *Staphylococcus aureus*: can the tissue injury be reduced by modulating the host's immune system? (O) 15
Tau, K.R., see Tang, Y.W. 334
Tian, X.C. and Yang, X.J., Life on the bio-pharm: therapeutic proteins from transgenic organisms (M) 424
Towbin, J.A., see Wang, Q. 382
Tuan, R.S., see Mariani, B.D. 207
Tuan, T-L. and Nichter, L.S., The molecular basis of keloid and hypertrophic scar formation 19

V
Vaira, D. and Ali, A., *Helicobacter pylori Protocols* (B) 237
van Deutekom, J.C.T., Hoffman, E.P. and Huard, J., Muscle maturation: implications for gene therapy (R) 214
van Noort, J.M., see Amor, S. 328
Varley, A.W. and Munford, R.S., Physiologically responsive gene therapy 445
Veggeberg, S.K., Blocking apoptotic damage after a heart attack (N) 278
Veggeberg, S.K., Lupus: complement cascade, Fc receptors... or both? (N) 184
Veggeberg, S.K., Molecular handles open the door to novel biomaterials and cancer therapies (N) 186
Veggeberg, S.K., Targeting toxins to brain tumors (N) 93
Vile, R.G., Sunassee, K. and Diaz, R.M., Strategies for achieving multiple layers of selectivity in gene therapy 84
Vousden, K.H., see Kubbutat, M.H.G. 250

W
Waanders, G.A., see Romero, P. 305
Wagner, H., see Tarkowski, A. 15
Wallace, R.W., Do oral bacteria cause cardiovascular disease? (N) 232
Wallace, R.W., The Human Genome Diversity Project: medical benefits versus ethical concerns 59
Wang, E., see Martin, G.M. 145
Wang, Q., Bowles, N.E. and Towbin, J.A., The molecular basis of long QT syndrome and prospects for therapy 382
Warren, A.J., A secretory clue to combined haemophilia (L) 235
Warren, A.J., Nanodroplet detection of novel cell-permeable ligands (L) 97
Warren, A.J., Transcription factor-directed therapeutics? (L) 463
Weinberg, A.D., Antibodies to the OX-40 (CD134) can identify and eliminate autoreactive T cells: implications for human autoimmune disease 76
Whitley, R.J., *Gene Therapy for Neurological Disorders and Brain Tumors* (B) 421
Widschwendter, M., Schröcksnadel, H. and Mörtl, M.G., Pre-eclampsia: a disorder of placental mitochondria? (O) 286
Willing, A.E., Cameron, D.F. and Sanberg, P.R., Sertoli cell transplants: their use in the treatment of neurodegenerative disease 471
Wood, K., Transplantation biology: recent advances (M) 56

X
Xing, Z., Adenoviral gene transfer to committed hematopoietic progenitors (L) 279
Xing, Z., Therapy for leukemia with a GM-CSF-tumor cell vaccine (L) 144

Y
Yang, X.J., see Tian, X.C. 424
Ye, S., Cole-Strauss, A., Frank, B. and Kmiec, E.B., Targeting gene correction: a new strategy for molecular medicine 431
Young, J. and Povey, S., The genetic basis of tuberous sclerosis 313

Z
Zavazava, N., Soluble HLA class I molecules: biological significance and clinical implications 116

SUBJECT INDEX

Compiled by Liza Weinkove
Abbreviations: (B), Books; (C), Letters; (E), Editorial; (L), Literature; (M), Meetings; (N), News; (O), Opinion; (P), Perspectives

A
actin
  WASP interaction 300
activins 257
acute lymphoblastic leukaemia
  E47-directed therapeutics (L) 463
acute myeloid leukaemia
  murine, GM-CSF-producing tumour cell vaccine (L) 144
adeno-associated viral vectors
  prostate cancer 494
  skeletal muscle 214
adenosine deaminase deficiency
  in utero gene therapy (N) 505
adenoviral vectors
  cancer gene therapy (L) 465
  committed haemopoietic progenitors (L) 279
  prostate cancer 494
  skeletal muscle 214
adhesion molecules
  as therapeutic targets in psoriasis (M) 512
aging
  cellular (M) 145
  and longevity (M) 145
  research (M) 466
AIDS *see also* HIV infection
  bone marrow cell xenografts 39
  gene therapy (M) 374
  restoring IL-2 production (N) 508
  role of endogenous cannabinoids (O) 196
alcohol consumption
  cardiovascular disease and (M) 9
  J-shaped mortality curve 9
alkaline phosphatase
  targeted gene conversion (L) 188
alkylguanine-DNA alkyltransferase
  engineered resistance to chemotherapy (L) 233
allergic disorders
  eotaxin receptors on Th2 cells (L) 187
alopecia
  hereditary (L) 143
aluminium
  in antiperspirants, toxic risks (O) 107
  routes of entry into body (O) 107
Alzheimer's disease
  α-synuclein and 438
  amyloid and protein kinase C isotypes (L) 279
  amyloid-β toxicity (L) 7
  antiperspirant use and (O) 107
  gene therapy 485
  molecular pathogenesis 151
  nerve cell xenografts 39
  protective effects of oestrogen (L) 281
  research in eastern Europe (N) 368
  treatment (B) 58
American Indians
  Human Genome Diversity Project and (C) 242
β-amyloid, Aβ, βAP
  in Alzheimer's disease 151
  intracellular binding protein (ERAB) (L) 7
  protein kinase C degradation and (L) 279
β-amyloid precursor protein, APP 151
  oestrogen-mediated secretion (L) 281
anaemia
  Fanconi's 201
  physiologically responsive gene therapy 445
anal fissures
  nitric oxide donor therapy (N) 94
anandamide
  in haemorrhagic shock (L) 99
  in HIV-mediated immune failure (O) 196
anergy
  MUC1-associated 397
Angelman syndrome
  imprinting defects (L) 464
angiogenesis
  anticancer therapy targeting (M) 514
  cardiovascular therapies targeting (M) 191
  inhibition, in cancer (L) 52
  oxygen-mediated regulation 122
  regulation of (B) 101
  -targeted therapy, and radiotherapy, in cancer (L) 371
angiostatin
  and radiotherapy, in cancer (L) 371
animal cell technology (M) 54
animal models
  aging (M) 466
  Chlamydia pneumoniae infection (O) 424
  Down syndrome (N) 414
  Fanconi's anaemia 201
  G_{M2} gangliosidoses 158
  immunological research 105
  multiple sclerosis (M) 328
  Niemann–Pick C disease 525
  osteoporosis (N) 3
ankylosing spondylitis
  HLA-B27 and molecular mimicry 540
antibiotics
  in cardiovascular disease (O) 424
  efflux-mediated resistance (L) 465
  resistance (L) 281
anticoagulant
  novel hookworm-derived, rNAPc2 (N) 4
antifungal drugs
  development (N) 50
  resistance (N) 275
anti-HIV drugs
  and passive immunotherapy, in HIV infection (O) 244
anti-idiotypic vaccines
  Chlamydia trachomatis 166
anti-inflammatory drug
  large-scale synthesis (N) 322
anti-inflammatory peptides (B) 373
antioxidants
  in noise-induced hearing loss (M) 284
antiperspirants
  risk of aluminium toxicity (O) 107
antisense hammerhead ribozymes
  in Marfan syndrome 376
antisense oligonucleotides
  in cancer therapy (M) 514
  in *mdx* mouse muscle cells (L) 419
aortic arch anomalies
  22q11 deletions 350
APC pathway
  c-*MYC* as target (L) 52
APO-1/Fas, CD95
  in immune evasion by tumours 63
apolipoprotein E, apoE, polymorphisms
  in Alzheimer's disease 151
  in ethnic Russians (N) 368

apoptosis
in Fanconi's anaemia 201
genes, identification and functional analysis 268
induction, in prostate cancer 494
myocardial ischaemia-reperfusion-related (N) 278
soluble HLA class I molecules and 116
appendicitis
rapid diagnosis (N) 367
2-arachidonylglycerol
in HIV-mediated immune failure (O) 196
arcuate nucleus
in sudden infant death syndrome (N) 49
arthritis
matrix metalloproteinases and TIMPs 130
reactive, HLA-B27 and molecular mimicry 540
Staphylococcus aureus (O) 15
arthroplasty
diagnosis of infection 207
aspirin
in cancer prevention (L) 510
asthma
inhibitory cytokines 452
atherosclerosis
Chlamydia pneumoniae as cause (O) 426
murine cell line model (N) 460
autoimmunity
cancer vaccines and 478
OX-40, CD134 antibodies 76
T-cell-directed biological agents 25
tolerance induction (M) 105
vs ulcerative colitis, in IL-2-deficient mice (L) 188
auto-proteolysis
p53 250
Axenfeld–Rieger anomaly (L) 372
axonal regeneration
in central nervous system (O) 337

B

baboons
bone gene studies (N) 3
bacteria
biofilm, in chronic middle ear infection (N) 141
commensal, engineered against biological warfare (N) 369
genomic sequencing (E) 1
inducing spondylarthropathies 540
oral, role in cardiovascular disease (N) 232
bacterial infections
prosthetic joint implants, diagnosis 207
Bacteroides fragilis
antibiotic sensitization (L) 281
baldness
hereditary (L) 143
basal cell carcinoma 343
BBIC
in inflammatory bowel disease (N) 461
B-cell chronic leukaemia
leukocyte depletion (N) 508
B cells
tolerization, for xenotransplantation (N) 462
Bcl-2 transgenic mice
resistance to neurotoxins (L) 371
Beckwith–Wiedemann syndrome 110
biofilm bacteria
in chronic middle ear infection (N) 141
biological warfare
protection against (N) 369
biomimicry
shell-crosslinked knedels (N) 321
bio-pharming (M) 424
bioreactors
second-generation (M) 424
biotechnology
animal cell (M) 54
bipolar disorder type I
candidate gene (L), (O) 189, 518
bladder cancer
noninvasive prognostic indicator (N) 506
blood–brain barrier
in multiple sclerosis (M) 328
blood substitute
for veterinary use (N) 139
blood vessels
collagen deposition 69
bone marrow failure
in Fanconi's anaemia 201
bone marrow transplantation
in Fanconi's anaemia 201
in G_{M2} gangliosidoses 158
bone morphogenetic proteins, BMPs 257
Borna disease virus (L) 142
boron-boosted fast neutron therapy 174
boron neutron capture therapy 174
brain trauma
gene therapy 485
brain tumours
boron neutron capture therapy 174
gene therapy (B) 421, 485
targeting toxins (N) 93
BRCA1/BRCA2
biological function 263
breast cancer
hereditary, genetic instability 263
molecular staging 389
natural history (M) 422
N-butyldeoxynojirimycin
in animal models of G_{M2} gangliosidoses 158

C

CAG trinucleotide repeats *see* trinucleotide repeats
calcium ions, Ca^{2+}
in Alzheimer's disease pathogenesis 151
calorie restriction
longevity and (M) 145
calpain
p53 degradation 250
CAMPATH-1H
clinical trials (N) 508
Canavan disease
gene therapy 485
cancer *see also specific cancers*
angiogenesis inhibition (L) 52
anti-angiogenic therapy and radiotherapy (L) 371
boron neutron capture therapy 174
cellular engineering approaches (N) 186
chemotherapy *see* chemotherapy
cytogenetic markers (B) 100
DAP kinase and 268
drug delivery by electroporation (N) 47
early detection methods (N) 324
gene therapy (M) 374
genetic instability 263
HPV-associated, predisposing p53 allele (L) 325
immune evasion mechanisms 63
immunotherapy 305, 397
molecular staging 389
natural history (M) 422
new molecular targets (M) 514
p53 gene replacement therapy (L) 174
role of epigenetics (M) 102
Smad mutations 257
TGF-β signalling pathway disruption 257
vaccines
based on dendritic cell fusions (L) 418
heat shock protein–peptide complexes 478
in murine leukaemia (L) 144
in prostate cancer 494
reductionist approach (M) 327
Cancer Genetics Network (N) 459
Candida albicans
antifungal drug resistance (N) 275
cannabinoids, endogenous
in haemorrhagic shock (L) 99
in HIV-mediated immune failure (O) 196
carbohydrates
large-scale synthesis (N) 322
carcinoma *in situ*
testicular 404
cardiology
molecular approaches in (M) 191
cardiovascular disease
alcohol consumption and (M) 9
Alzheimer's disease and 151
Chlamydia pneumoniae as cause (O) 426
new markers (N) 415

novel therapeutic approaches (M) 191
oral bacteria and (N) 232
role of gap junctions (M) 192
single-gene disorders causing (M) 191
cartilage
destruction in joint disease 130
regeneration, collagen scaffold (N) 96
cataracts
role of gap junctions (M) 192
cathepsin D
role in apoptosis 268
cationic lipids, novel, lipitoids
as non-viral vectors (L) 418
cationic liposomes *see* liposomes, cationic
CCR *see* chemokine receptors
$CD4^+$ T cells
autoreactive, OX-40 antibodies 76
CD15 antibodies
diagnosis of appendicitis (N) 367
CD44
variant isoform 7 (L) 419
CD95 system
in immune evasion by tumours 63
CD134, OX-40
antibodies to 76
CD154
in chronic lymphocytic leukaemia (L) 7
Cdc42
WASP interactions 300
CDKN2 gene (E) 1
cell cycle
in Fanconi's anaemia 201
novel anticancer therapies targeting (M) 514
cells
microencapsulation of genetically engineered 221
programmed death *see* apoptosis
surface engineering (N) 186
cellular therapies
G_{M2} gangliosidoses 158
microencapsulated cells 221
novel approaches (M) 146
central nervous system, CNS *see also* brain tumours; neurodegenerative diseases
gene delivery strategies 158
gene therapy 485
inflammation, in Alzheimer's disease 151
injury response, Alzheimer's disease and 151
regeneration/repair (L) 98
restricted inflammatory response (O) 337
cerebral amyloid angiopathy
Alzheimer's disease and 151
cerebral blood flow
in Huntington's disease 532
cerebral metabolism
in Huntington's disease 532
cervical cancer
natural history (M) 422
CFTR gene transfer 292
chaperones
heat shock proteins as 478
Charcot–Marie–Tooth syndrome (M) 192
chemokine receptors
CCR-3, on Th2 cells (L) 187
CCR-5
blocking antibodies (N) 507
gp120 signalling in HIV infection (O) 196
chemotherapy
alternative to Taxol (N) 460
delivery by electroporation (N) 47
engineering resistance to (L) 233
localized, in pancreatic cancer (M) 146
testicular germ cell tumours 404
chimeric oligonucleotides
in targeted gene repair 431
chimerism
after *in vitro* fertilization (L) 143
Chlamydia pneumoniae
as cause of atherosclerosis (O) 426
Chlamydia trachomatis
immune responses 166
vaccines 166
cholesterol
handling, in Niemann–Pick C disease 525
regulation (L) 51
thyroid hormone analogue (L) 370
chromium release assays
antigen-specific cytotoxic T cells 305
chromosome 22q11 deletions
congenital heart defects 350
chromosome-instability syndromes (M) 240
chronic lymphocytic leukaemia
immunodeficiency in (L) 7
cisplatin
in testicular germ cell tumours 404
collaboration
academic–industry, in genetic research (P) 148
collagen
cardiovascular, mechanical forces regulating 69
-derived peptides, in cardiovascular remodelling (N) 415
scaffold, knee cartilage repair (N) 96
collagenases
in joint diseases 130
colorectal cancer
aspirin in prevention (L) 510
crosstalk among signalling pathways (L) 511
molecular staging 389
commensal bacteria
engineered against biological warfare (N) 369
commercialization
of human genetics (P), (C) 148, 335, 336
complement cascade
in systemic lupus erythematosus (N) 184
computer-assisted drug design 358
congenital heart disease
22q11 deletions 350
connexins
in health and disease (M) 192
conotruncal anomaly face syndrome 350
coronary heart disease
alcohol consumption and (M) 9
Chlamydia pneumoniae as cause (O) 426
new markers (N) 415
regulated gene therapy (N) 183
cortisol levels
memory impairment related to (L) 326
Crohn's disease
protease inhibitors (N) 461
csp locus
Streptococcus pneumoniae (L) 99
cutis laxa
elastin gene mutation (L) 325
CXCR4
gp120 signalling in HIV infection (O) 196
cystic fibrosis
elastase inhibitor (N) 5
gene therapy 292
cystic fibrosis transmembrane conductance regulator, CFTR 292
cystinosis, nephropathic
gene localization (M) 238
cytogenetics
cancer (B) 100
testicular germ cell tumours 404
cytokines
in antigen-specific cytotoxic T cells 305
inhibitory, in asthma 452
knockout mice (B) 282
regulation of gene therapy 445
as therapeutic targets in psoriasis (M) 512
cytoskeleton
WASP interactions 300
cytotoxic T cells
cancer immunotherapy 305

D

DAP genes
identification and functional analysis 268
DAP-kinase 268
deafness
hereditary (L), (M) 52, 192
in long QT syndrome 382
noise-induced (M) 284

death-associated proteins, DAPs 268
dendritic cells
cancer vaccines using (L) 418
dentatorubral pallidoluysian atrophy
role of transglutaminases (L) 187
developmental disorders
after gene therapy (O) 468
Sonic hedgehog pathway and 343
development, early human
molecular genetics (B) 420
diabetes mellitus
insulin-dependent, genetic susceptibility (L) 417
islet cell xenografts 39
physiologically responsive gene therapy 445
diarrhoea
rotavirus (L) 6
differential display methods (B) 13
DiGeorge syndrome 350
DNA
automated sequence analysis (M) 146
bacterial, in septic shock 15
cationic liposome complexes (L) 370
compaction, for non-viral gene transfer (N) 323
methylation, role in cancer (M) 102
mitochondrial 31
random integration of foreign (O) 468
transfer into mitochondria 31
DNA repair
in Fanconi's anaemia 201
as gene therapy strategy 431
role of BRCA1/BRCA2 263
DNA–RNA hybrid oligonucleotides
in gene conversion (L) 188
in targeted gene repair 431
dopamine receptors
in Huntington's disease 532
double-strand conformation analysis (L) 142
Down syndrome
mouse model (N) 414
drugs
delivery
by electroporation (N) 47
shell-crosslinked knedels (N) 321
design, transcription factor-based (L) 358, 463
discovery, yeast Genome Reporter Matrix system (N) 48
Duchenne muscular dystrophy
antisense therapy (L) 419
gene therapy 214
dynamic molecular combing (N) 2
dystrophin gene
induced alternative splicing (L) 419
transfer strategies 215

E

E47
β-sheet peptide inhibitor (L) 463
E6AP
regulation of p53 protein 250
E-cadherin gene mutations
in hereditary stomach cancer (N) 276
eclampsia
mitochondrial hypothesis (O) 286
efflux pumps
in antibacterial resistance (L) 465
efflux transporter genes
in antifungal drug resistance (N) 275
Eker rat 313
elastase inhibitor, EPI-HNE-4 (N) 5
elastin (L) 325
electronic zoo blotting (L) 463
electroporation
anti-cancer drug delivery (N) 47
ELISPOT assay
antigen-specific cytotoxic T cells 305
embryogenesis
human (B) 420
embryos
alteration by gene therapy DNA (O) 468
endocrinology (B) 12
endocytosis
regulation by tuberin 313
endoplasmin 478
endothelial cells
aging (M) 466
enzyme replacement therapy
in G_{M2} gangliosidoses 158
eotaxin receptors
on Th2 cells (L) 187
epigenetics
role in cancer (M) 102
EPI-HNE-4 (N) 5
epilepsy
sodium channel β1 subunit gene mutation (L) 417
epithelial cells
in blood, for early cancer detection (N) 324
epothilones
biosynthesis (N) 460
Epstein–Barr virus
in X-linked lymphoproliferative disease (L) 510
ERGIC-53
in combined haemophilia (L) 235
erythropoiesis
stimulation in hypoxia 122
erythropoietin
oxygen-mediated regulation 122
Escherichia coli
enteropathogenic (L) 233
microencapsulated, in uraemia 221
type I fimbriae *in vivo* (L) 370
uropathogenic, virulence factors (L) 6
EspA/EspB proteins (L) 233
experimental allergic encephalomyelitis, EAE
OX-40 antibody therapy 76
therapeutic strategies (M) 328
uric acid therapy (L) 144
experimental colitis
anti-CD44v7 antibody therapy (L) 419
expressed sequence tags
data organization (L) 235
extracellular matrix
degradation, anticancer therapy targeting (M) 514
mature skeletal muscle 214
remodelling in tissue repair 19

F

factor V/factor VIII
combined deficiency (L) 235
factor IX
targeted gene conversion (L) 188
Fanconi's anaemia 201
Fas
in immune evasion by tumours 63
fast neutron therapy
boron-boosted 174
Fc receptors
in systemic lupus erythematosus (N) 184
fetal cells
in maternal blood (L) 7
fetal cell transplants
neural, Sertoli cell transplants with 471
in Parkinson's disease 39
in spinal cord injury (L) 98
fetus
gene therapy (N) 505
haemopoietic stem cell transplantation (M) 10
fibrillin 1
mutations 376
ribozymes targeting 376
fibroblasts
cardiovascular, regulation of function 69
hypertrophic scar and keloid 19
fibrosis
cardiovascular, mechanical forces inducing 69
excessive skin 19
fimbriae
E.coli type I, *in vivo* expression (L) 370
flow cytometry
antigen-specific cytotoxic T cells 305
fluorescent antigen ligands
antigen-specific cytotoxic T cells 305
fluorescent *in situ* hybridization, FISH
dynamic molecular combing (N) 2
peptide-nucleic acid technology (N) 231
forkhead transcription factor (L) 372
free radicals
noise-induced hearing loss and (M) 284

functional imaging
in Huntington's disease 532
fungal infections
new strategies (N) 50
funding
in eastern Europe (N) 268
private sector (P) 148
fusion proteins
tolerogenic 25

G

galactosyl-α-1,3-galactose, αGal
B-cell tolerization (N) 462
ganglioside G_{M2}
excessive accumulation 158
gap junctions
in health and disease (M) 192
GDI1 mutations
in X-linked mental retardation (L) 511
gelatin–DNA nanospheres (L) 464
gene
chips, vascular smooth muscle cells (N) 460
conversion, by chimeric DNA/RNA oligonucleotides (L) 188
correction, targeted 431
modifying, in spinal muscular atrophy (L) 463
transfer vectors *see* vectors
gene expression
detecting differences (B) 13
oxygen-regulated 122, 445
physiologically regulated 445
regulation (B) 236
GeneMap98 web site (N) 509
Gene Protection Initiative
Swiss (E), (C) 1, 14
Genes and disease web site (N) 509
gene therapy
brain targeting (B) 421
central nervous system 485
in chemotherapy resistance (L) 233
concepts (B) 190
cystic fibrosis 292
in Duchenne muscular dystrophy (L) 419
ex vivo (M) 146
Fanconi's anaemia 201
gene delivery systems (M) 374
germline alteration by (O) 468
G_{M2} gangliosidoses 158
hypoxia-regulated (N) 183
in utero (N) 505
lentiviral vectors (L) 51
lipitoids as vectors (L) 418
long QT syndrome 382
Marfan syndrome 376
microencapsulated cells 221
mitochondrial disorders 31
muscle disorders 214
non-viral vectors (N) 323
physiologically responsive 445
prostate cancer 494
skeletal muscle-based 214
targeted gene correction 431
targets (M) 374
TP53 (L) 465
vector targeting strategies 84
Wiskott–Aldrich syndrome 300
genetics
cancer, network (N) 459
commercialization of (P), (C) 148, 335, 336
diagnostic services, premature implementation (P) 148
genital tract infections
chlamydial 166
genome caretakers
BRCA1/BRCA2 proteins 263
Genome Reporter Matrix system (N) 48
genomics
comparative (L) 463
expanding areas (L) 235
functional (M) 146, 238
web sites (M) 240
germ cell tumours
testicular 404
germline
alteration by somatic gene therapy (O) 468
glaucoma
aging changes and (M) 466
hereditary (L) 372
GLI3 mutations 343
glioblastoma multiforme
boron neutron capture therapy 174
gliomas
targeting toxins to (N) 93
glucose
cerebral metabolism, in Huntington's disease 532
regulation of gene therapy 445
glutathione
oestrogen-mediated neuroprotection and (L) 281
G_{M2} gangliosidoses
biology and treatment strategies 158
Gorlin syndrome 343
gp96, endoplasmin 478
gp120
in endogenous cannabinoid production (O) 196
graft rejection
biology (M) 56
T-cell-directed biological agents 25
granulocyte–macrophage colony-stimulating factor, GM-CSF
in AIDS/HIV infection (N) 508
tumour cell vaccine producing (L) 144
green fluorescent protein
adenoviral transfer (L) 279
Greig syndrome 343
growth factors
transplanted Sertoli cells 471
growth hormone, human, hGH
orally activated therapy (N) 95
in urine of transgenic mice (N) 230
grp75 479

H

haemoglobin
modified bovine (N) 139
haemophilia
combined, genetic basis (L) 235
Haemophilus influenzae
in chronic middle ear infection (N) 141
haemopoietic progenitors, committed
adenoviral gene transfer (L) 279
haemorrhagic shock
endogenous cannabinoids (L) 99
hairless gene
human homologue (L) 143
hamartin 313
hammerhead ribozymes
in Marfan syndrome 376
Hayflick limit (M) 145
HCgp39
rheumatoid arthritis therapy based on (N) 277
head and neck cancer
p53 gene replacement therapy (L) 174
hearing loss *see also* deafness
noise-induced (M) 284
heart
collagen deposition 69
development, genes involved (M) 191
heart disease
congenital, 22q11 deletions 350
heat shock proteins 478
70, Hsp70 478
90, Hsp90 478
noise-induced hearing loss and (M) 284
–peptide complexes, HSPPCs 478
Helicobacter pylori
new treatments (M) 240
protocols (B) 237
hemihyperplasia, hemihypertrophy 110
hepatocytes
xenografts in liver failure 39
HERG gene 382
hermaphroditism
true (L) 143
herpes simplex virus, HSV
-based vectors, skeletal muscle 214
ICP47 protein (L) 8
β-hexosaminidase
hereditary deficiency 158
replacement therapy 158
high density lipoprotein receptor
scavenger receptor class B type I (L) 51
hippocampus
effects of stress (L) 326
HIV infection *see also* AIDS
antiviral therapy, passive immunotherapy with (O) 244
CCR-5 blocking antibodies (N) 507
gene therapy 374
plasmapheresis (O) 244
role of endogenous cannabinoids (O) 196

HLA-B27 polymorphism
in spondylarthropathy 540
HLA class I molecules
soluble 116
holoprosencephaly
Sonic hedgehog and 343
homeotic genes
human (B) 420
homologous recombination
gene targeting via 431
hookworms
recombinant anticoagulant protein, rNAPc2 (N) 4
hSKCa3 gene
in schizophrenia and bipolar disorder (L), (O) 189, 518
Human Genome Diversity Project (P), (C) 59, 242, 243
Human Genome Project
annual HUGO meeting (M) 238, 312
data disclosure (C) 335, 336
human immunodeficiency virus infection *see* HIV infection
human papillomavirus-associated cancer
natural history (M) 422
predisposing p53 allele (L) 325
Huntington's disease
functional imaging 532
toxicity of triplet repeats (L) 280
hypertrophic scars
molecular basis 19
hypoxia
regulation of gene expression 122, 445
hypoxia-inducible factor 1, HIF-1 122
hypoxia-response elements, HRE
in gene therapy regulation (N) 183

I

ICP47 protein
herpes simplex virus (L) 8
immune evasion
by tumours 63
immune privilege
CNS, effect on axonal regeneration (O) 337
immune regulation
role of mucins 397
immunodeficiency *see also* AIDS
in chronic lymphocytic leukaemia (L) 7
in Wiskott–Aldrich syndrome 300
immunological tolerance *see* tolerance, immunological
immunoprotection
from transplanted Sertoli cells 471
immunosuppression
MUC1-mediated 397
immunosuppressive therapy
T-cell targeted, in rheumatoid arthritis (N) 277
immunotherapy
cancer 305, 397
inflammatory bowel disease (L) 419
passive, in HIV infection (O) 244
imprinting
IGF2 gene 110
in Prader–Willi and Angelman syndromes (L) 464
indigenous populations
Human Genome Diversity Project (P), (C) 59, 242
infections
molecular diagnosis (B) 334
prosthetic joint implants, diagnosis 207
infectious agents *see also* bacteria
as cause of atherosclerosis (O) 426
inducing spondylarthropathies 540
inflammation
CNS, in Alzheimer's disease 151
-inducible expression systems 445
integrin-based therapies (M) 194
restricted, in CNS (O) 337
inflammatory bowel disease
anti-CD44v7 antibody therapy (L) 419
protease inhibitors (N) 461
insulin
plasma levels, as cardiovascular risk factor (N) 415
insulin-like growth factor 1
in human fetal growth 110
insulin-like growth factor 2, IGF2
in human fetal growth 110
in overgrowth disorders 110
integrins
therapeutic approaches based on (M) 194
intercellular adhesion molecules, ICAM
inhibitors (M) 194
interferon-γ
apoptosis induction 268
in asthma 452
interleukin 1 receptor antagonist
in asthma 452
interleukin 2, IL-2
-deficient mice, ulcerative colitis (L) 188
restoring production, in AIDS (N) 508
interleukin 4
in asthma 452
interleukin 10
in asthma 452
interleukin 12
in asthma 452
interleukin 13
in asthma 452
interleukin 18
in asthma 452
in utero
gene therapy (N) 505
haemopoietic stem cell transplantation (M) 10
in vitro fertilization
chimeric embryos (L) 143
ion channels *see* potassium channels; sodium channels
iridogoniodysgenesis (L) 372
ischaemia
in gene therapy switching (N) 183
physiologically responsive gene therapy 445
ischaemia-reperfusion injury
myocardial (N) 278
ischaemic heart disease *see* coronary heart disease
islets of Langerhans
xenografts 39

J

Jervell and Lange–Nielsen syndrome 382
joint disease *see also* arthritis
matrix metalloproteinases and TIMPs 130
joint implants, prosthetic
diagnosis of infection 207

K

kainate receptors
in sudden infant death syndrome (N) 49
KCNN3 gene
in schizophrenia and bipolar disorder (L), (O) 189, 518
keloids
molecular basis 19
keratinocyte growth factor 2, KGF-2
therapeutic use (N) 229
Klotho mouse (M) 466
knee cartilage
regeneration (N) 96
knockout mice
cytokine (B) 282

L

lentiviral vectors (L) 51
Lesch–Nyhan syndrome
gene therapy 485
leukaemia
acute lymphoblastic, E47-directed therapeutics (L) 463
B-cell chronic, leukocyte depletion (N) 508
chronic lymphocytic, immunodeficiency in (L) 7
murine acute myeloid, GM-CSF-producing tumour cell vaccine (L) 144
leukocyte function-associated antigen inhibitors (M) 194
N-levulinoyl mannoside (N) 186
Lewy bodies
component proteins 438
limb development
Sonic hedgehog pathway and 343
limiting dilution analysis
tumour antigen-specific cytotoxic T cells 305
lipid polycation DNA vectors (N) 323
lipitoids
as non-viral vectors (L) 418

lipoplexes (L) 370
lipoproteins
plasma (N) 413
liposomes, cationic
CFTR gene transfer 292
DNA interactions (L) 370
in endobronchial cancer (L) 464
improved, for gene delivery (N) 323
in prostate cancer gene therapy 494
in targeted gene correction 431
lissencephalin-X gene (M) 238
Listeria monocytogenes
as vaccine vector (M) 240
liver failure
hepatocyte xenotransplants 39
locus of enterocyte attachment, LEE
enteropathogenic *E. coli* (L) 233
long QT syndrome
molecular basis 382
low density lipoprotein-cholesterol
processing in Niemann–Pick C disease 525
lung
CFTR gene transfer 292
lung cancer
boron-boosted fast neutron therapy 174
molecular staging 389
p53 gene replacement therapy (L) 465
lupus erythematosus, systemic
role of Fc receptors (N) 184
lymphocytes
depletion in leukaemia and multiple sclerosis (N) 508
lymphoproliferative disease
X-linked (L) 510
lysophosphatidic acid
anti-apoptotic activity (N) 278
lysosomes
cholesterol accumulation, in Niemann–Pick C disease 525

M

macrophages
in axonal response to injury (O) 337
HIV-mediated endogenous cannabinoid production (O) 196
major histocompatibility complex, MHC
soluble molecules 116
major outer membrane protein, MOMP
Chlamydia vaccines based on 166
malnutrition
in mouse model of Down syndrome (N) 414
Maori family
stomach cancer gene (N) 276
Marfan syndrome
RNA-based therapy 376
marijuana
medicinal use (O) 196
matrix metalloproteinases, MMPs
in joint diseases 130
Mdm2
control of p53 degradation 250
mdx mouse muscle cells
antisense therapy (L) 419
mechanical forces
cardiovascular collagen deposition and 69
medical genetics (B) 333
melanoma
boron neutron capture therapy 174
molecular staging 389
memory impairment
stress-related (L) 326
meniscal cartilage
regeneration (N) 96
mental retardation
X-linked (L) 511
metastasis
role of DAP-kinase 268
suppression, in prostate cancer 502
methylation
role in cancer (M) 102
microarray chip technology (M) 238, 312
microencapsulation
genetically engineered cells 221
microfibrils
in Marfan syndrome 376
microglia
in axonal response to injury (O) 337
microsatellite DNA instability
effects of aspirin (L) 510
minK 382
mismatch repair mutations
effects of aspirin (L) 510
mitochondria 31
age-related dysfunction, in Alzheimer's disease 151
gene delivery to 31
genome 31
mitochondrial disorders
gene therapy 31
in pre-eclampsia pathogenesis (O) 286
molecular diagnosis
infectious diseases (B) 334
long QT syndrome 382
molecular medicine (M) 146, 240
molecular mimicry
in spondylarthropathies 540
molecular staging
cancer 389
monoclonal antibodies
tolerogenic 25
MUC1
in cancer immunotherapy 397
in cancer vaccine (L) 418
mucins
biological role 397
mucopolysaccharidosis VII
gene therapy 485
multiple sclerosis
CAMPATH-1H therapy (N) 508
experimental models (M) 328
medicinal marijuana use (O) 196
OX-40, CD134 antibodies 76
uric acid and (L) 144
muscle, skeletal
maturation 214
viral gene therapy 214
mutagenesis
site-directed *in vivo* (L) 188
mutations
correction methods (L) 188, 233
double-strand conformation analysis (L) 142
and protein dysfunction (B) 517
targeted correction 431
c-*MYC*
APC pathway target (L) 52
Mycobacterium tuberculosis
drug targets and vaccines (M) 104
genome and virulence (M) 330
host response to infection (M) 330
myocardial infarction
anti-apoptotic therapy (N) 278
myotonic dystrophy protein kinase gene, *DMPK*
ribozyme-mediated *trans*-splicing (L) 233

N

naevoid basal cell carcinoma syndrome 343
nanodroplets
novel cell-permeable ligand detection (L) 97
nano-dumplings (N) 321
nanospheres
DNA–gelatin (L) 464
National Cancer Institute
Cancer Genetics Network (N) 459
National Center for Biotechnology Information
Genes and disease web site (N) 509
National Research Council
report on Human Genome Diversity Project (P), (C) 59, 242, 243
natural killer cells
in psoriasis (M) 512
nematode anticoagulant protein, NAPc2
recombinant (N) 4
neural crest cells
cardiac, defects in migration 350
neurodegenerative diseases *see also* Alzheimer's disease; G_{M2} gangliosidoses; trinucleotide repeats
cellular therapies (M) 146
gene therapy 485
nerve cell xenografts 39
Niemann–Pick C disease 525
role of α-synuclein 438
Sertoli cell transplants 471
neurofibrillary tangles 151
neurogenetic disorders
gene therapy 485
neurological disorders
gene therapy (B) 421, 485
neuropsychiatric disease
Borna disease virus and (L) 142
ion channels in (L), (O) 189, 518

NF-IL6
as retinoid target in psoriasis (L) 234
NF-κB
as target in drug design 358
Niemann–Pick C disease 525
nitric oxide, NO
donors, for anal fissures (N) 94
in pre-eclampsia pathogenesis (O) 286
noise-induced hearing loss (M) 284
non-disclosure agreements (P) 148
non-isotopic RNase cleavage assay, NIRCA
in bladder cancer (N) 506
non-obese diabetic, NOD mouse
comparative gene mapping (L) 417
NPC1 gene 525
nuclear magnetic resonance spectroscopy
plasma lipoproteins 413
nutrition
in mouse model of Down syndrome (N) 414
N-WASP 300

O

obesity
uncoupling protein homologue (N) 185
oestrogen
neuroprotective effects (L) 281
oligonucleotides
DNA–RNA *see* DNA–RNA hybrid oligonucleotides
Oligophrenin-1
in X-linked mental retardation (L) 511
oncogenes
prostate cancer gene therapy targets 494
oocytes
alteration by gene therapy DNA (O) 468
orally activated protein therapy (N) 95
orthopaedic surgery
diagnosis of infections 207
osteoarthritis
matrix metalloproteinases and TIMPs 130
osteoporosis
genetic studies in baboons (N) 3
otitis media with effusion
biofilm bacteria (N) 141
overgrowth
IGF2-associated 110
OX-40
antibodies to 76
oxidative stress
in Parkinson's disease (L) 371
oxygen
cytotrophoblast function and (O) 286
metabolism, in Fanconi's anaemia 201
regulation of gene expression 122, 445
Oxyglobin
a blood substitute (N) 139

P

p16 (E) 1
p53, TP53
allele, HPV-associated cancer and (L) 325
gene, liposome-based delivery (L) 464
gene replacement therapy (L) 465
mutations, in bladder cancer (N) 506
protein, regulation of stability 250
in testicular germ cell tumours 404
PAK3 mutations
in X-linked mental retardation (L) 511
Pallister–Hall syndrome 343
pancreatic cancer
localized chemotherapy (M) 146
molecular staging 389
parkin gene 438
parkinsonism
autosomal-recessive juvenile, ARJP 438
Parkinson's disease
familial, genetic dissection 438
fetal nerve cell grafts 39
gene therapy 485
oxidative stress (L) 371
Sertoli cell transplants 471
passive immunotherapy
in HIV infection (O) 244
patched, *PTC* gene mutations 343
Pax8 mutations (M) 238
PCR *see* polymerase chain reaction
pelvic inflammatory disease
chlamydial 166
Pendred syndrome (L) 52
penetrance
tuberous sclerosis 313
peptide-based cancer vaccines (M) 327
peptide-nucleic acid technology (N) 231
peptides
heat shock protein complexes 478
proinflammatory and anti-inflammatory (B) 373
periodontal disease
role in cardiovascular disease (N) 232
Peutz–Jeghers syndrome
serine/threonine kinase mutations (L) 97
phage display library
CCR-5 blocking antibodies 507
pharmaceuticals
from transgenic organisms (M) 424
phosphoinositides
WASP interaction 300
photodynamic therapy
in psoriasis (N) 416
phylogenomics (L) 235
physiologically responsive gene therapy, PRGT 445
pig
endogenous retroviruses (L) 280
placental mitochondria
defects in pre-eclampsia (O) 286
plasmapheresis
therapeutic, in HIV infection (O) 244
plasmid vectors
targeted, for gene therapy 84
platelet aggregation-associated protein, PAAP (N) 232
pneumococci
vaccine evasion (L) 99
polydactyly
isolated postaxial 343
polyketides
biosynthesis (N) 460
polymerase chain reaction, PCR
antigen-specific cytotoxic T cells 305
diagnosis of arthroplasty infections 207
Helicobacter pylori (B) 237
molecular staging in cancer 389
polymorphisms
double-strand conformation analysis (L) 142
population diversity
Human Genome Diversity Project (P), (C) 59, 242, 243
positron emission tomography, PET
in Huntington's disease 532
potassium channels
KVLQT1 gene 382
minK 382
in schizophrenia and bipolar disorder (L), (O) 189, 518
poxvirus vectors
prostate cancer 494
Prader–Willi syndrome
imprinting defects (L) 464
pre-eclampsia
mitochondrial hypothesis (O) 286
prenatal diagnosis
fetal cells in maternal blood (L) 7
presenilins
in Alzheimer's disease (N) 151, 368
proinflammatory peptides (B) 373
prostate cancer
gene therapy 494
molecular staging 389
prosthetic joint implants
diagnosis of infection 207
protease inhibitors
in inflammatory bowel disease (N) 461
proteasome
p53 degradation 250
protein kinase C degradation
effects of soluble β-amyloid (L) 279
proteins
dysfunction, in human genetic disease (B) 517
nitration in Parkinson's disease (L) 371

orally activated therapy (N) 95
therapeutic, from transgenic organisms (M) 424
in urine of transgenic mice (N) 230
proton nuclear magnetic resonance spectroscopy
plasma lipoproteins 413
P-selectin polymorphisms
in cardiovascular disease (N) 415
Pseudomonas aeruginosa
efflux-mediated multidrug resistance (L) 465
psoriasis
NF-IL6 as retinoid target (L) 234
pathogenesis and therapy (M) 512
photodynamic therapy (N) 416
PTC mutations 343
pyrimidines
urinary, in early cancer detection (N) 324

R

Rab5
tuberin interaction 313
Rabaptin-5
tuberin interaction 313
Rab GDP-dissociation inhibitor
in X-linked mental retardation (L) 511
Rad51
BRCA1 interaction 263
radioimaging
in appendicitis (N) 367
radiotherapy
and anti-angiogenic therapy, in cancer (L) 371
rapamycin
in orally activated protein therapy (N) 95
RB mutations
in testicular germ cell tumours 404
reactive arthritis
HLA-B27 and molecular mimicry 540
renal failure
microencapsulated *E. coli* DH5 cells 221
reperfusion injury
Cylexin therapy (N) 322
respiratory tract
CFTR gene transfer 292
restriction fragment target assay, RFTA (N) 140
retinitis pigmentosa
autosomal dominant (L) 53
retinoids
target in psoriasis (L) 234
retroviral vectors
prostate cancer 494
skeletal muscle 214
targeting strategies 84
retroviruses
endogenous, risks of xenotransplantation (L) 280
reference book (B) 283
reverse-transcription–polymerase chain reaction, RT-PCR
molecular staging in cancer 389
rheumatoid arthritis
boron neutron capture therapy 174
matrix metalloproteinases and TIMPs 130
targeted immunosuppressant therapy (N) 277
ribozymes
in Marfan syndrome 376
trans-splicing of trinucleotide repeat (L) 233
RNA
catalytic *see* ribozymes
–DNA hybrid oligonucleotides *see* DNA–RNA hybrid oligonucleotides
Romano–Ward syndrome 382
rotaviruses
pathogenesis (L) 6
RP11 locus mutations (L) 53

S

Saccharomyces cerevisiae
Genome Reporter Matrix (N) 48
Sandhoff disease 158
scars
hypertrophic 19
scavenger receptor class B type I (L) 51
schizophrenia
candidate gene (L), (O) 189, 518
secretory vesicle assay (N) 275
seizures, febrile
sodium channel β1 subunit gene mutation (L) 417
seminomas 404
senescence
cellular (M) 466
senile plaques 151
septic shock
Staphylococcus aureus (O) 15
serial analysis of gene expression, SAGE (M) 238
serine/threonine kinase mutations
in Peutz–Jeghers syndrome (L) 97
Sertoli cell transplants 471
severe combined immunodeficiency, SCID
in utero gene therapy (N) 505
SH2 domain
in X-linked lymphoproliferative disease (L) 510
SH3-domain-containing proteins
WASP interactions 300
shell-crosslinked knedels (N) 321
SHH gene mutations 343
shock
haemorrhagic, endogenous cannabinoids (L) 99
septic, *Staphylococcus aureus* (O) 15
sialic acid
cell-surface expression 186
sib-pair analysis
in insulin-dependent diabetes mellitus (L) 417
signal transduction pathways
novel anticancer therapies targeting (M) 514
Simpson–Golabi–Behmel syndrome 110
single photon emission tomography, SPET
in Huntington's disease 532
skin
aluminium uptake through (O) 107
skin cancer
drug delivery by electroporation (N) 47
natural history (M) 422
SLAM-associated protein, SAP (L) 510
Smad proteins
in cancer 257
in colorectal cancer (L) 52
in TGF-β signalling 257
sodium channels
SCN1B gene (L) 417
SCN5A gene 382
Sonic hedgehog, Shh
human developmental disorders and 343
sperm
alteration by gene therapy DNA (O) 468
spinal and bulbar muscular atrophy
toxicity of triplet repeats (L) 280
spinal cord injury
cellular therapies (M) 146
fetal cell transplants (L) 98
spinal muscular atrophy
candidate modifying gene (L) 463
splicing
modified, in *mdx* mouse muscle cells (L) 419
ribozyme-mediated *trans* (L) 233
split-pool synthesis
nanodroplet detection of ligands (L) 97
spondylarthropathies
HLA-B27 and molecular mimicry 540
Staphylococcus aureus
arthritis and sepsis (O) 15
vaccine and therapy (L) 281
STATs
as targets in drug design 358
stem cells
haemopoietic, *in utero* transplantation (M) 10
neural, CNS transplants (L) 98
stomach cancer gene (N) 276
Streptococcus pneumoniae
vaccine evasion (L) 99
Streptococcus sanguis
role in cardiovascular disease (N) 232

stress
memory impairment related to (L) 326
striatal function
in Huntington's disease 532
subunit vaccines
Chlamydia trachomatis 166
sudden death
in long QT syndrome 382
sudden infant death syndrome
in long QT syndrome 388
molecular basis (N) 49
Sugar Nucleotide Cycling technology (N) 322
sulphate transporter gene mutations
in Pendred syndrome (L) 52
superantigen
in staphylococcal infections (O) 15
supravalvular aortic stenosis
elastin gene mutation (L) 325
Switzerland
Gene Protection Initiative (E), (C) 1, 14
α-synuclein
in Parkinson's disease 438
systemic lupus erythematosus
role of Fc receptors (N) 184

T

TAP
HSV ICP47 interaction (L) 8
target protection assay, TPA (N) 140
tau protein
in Alzheimer's disease (N) 368
Taxol
biosynthesis of alternative to (N) 460
Tay–Sachs disease 158
T cells
anergy, MUC1-associated 397
autoreactive, OX-40 antibodies 76
rheumatoid arthritis-causing, targeted therapy (N) 277
soluble HLA class I molecules and 116
as therapeutic targets in psoriasis (M) 512
tolerogenic biological agents targeting 25
in transplantation biology (M) 56
tumour cell responsiveness 63
^{99m}-technetium imaging
in appendicitis (N) 367
technical knockout, TKO, strategy
apoptosis genes 268
technology transfer (M) 240
telomeres
as cell 'replicometer' (M) 466
shortening, and aging (M) 145
testicular germ cell tumours 404
tetralogy of Fallot
22q11 deletions 350
α-thalassaemia
in utero gene therapy (N) 505
T helper type 1, Th1, cells
anti-CD44v7 antibody therapy and (L) 419
T helper type 2, Th2, cells
CCR3 eotaxin receptors (L) 187
thrombocytopenia
in Wiskott–Aldrich syndrome 300
thyroid hormone receptor
high affinity agonist (L) 370
tissue inhibitors of metalloproteinases, TIMPs
in joint disease 130
tissue regeneration
in CNS (O) 337
integrin receptor agonists stimulating (M) 194
tolerance, immunological
B cell, for xenotransplantation (N) 462
biological agents inducing 25
mechanisms and applications (M) 105
soluble HLA class I molecules 116
TonB
Pseudomonas aeruginosa (L) 465
torsade de pointes 382
toxins
targeting to brain tumours (N) 93
TP53 see p53
trachoma
Chlamydia vaccines 166
transcription factors
agents modulating 358
in gene regulation (B) 236
gene-specific, as drug targets (L) 358, 463
transforming growth factor β, TGF-β
in asthma 452
in keloid formation 19
signalling pathways 257
transgenes
physiological regulation of expression 445
transgenic animals
random DNA integration (O) 468
vs animal cells (M) 54
transgenic mice
Bcl-2-expressing (L) 371
therapeutic protein production (N) 230
transgenic organisms
Swiss Gene Protection Initiative (E), (C) 1, 14
therapeutic proteins from (M) 424
transglutaminases
role in CAG-repeat diseases (L) 187
transplantation
biology (M) 56
CNS (L) 98
fetal cell *see* fetal cell transplants
in utero, haemopoietic stem cells (M) 10
Sertoli cell 471
soluble HLA class I molecules 116
T-cell-directed biological agents 25
tolerance induction (M) 105
transporter associated with antigen processing *see* TAP
trinitrobenzenesulfonic acid-induced colitis
anti-CD44v7 antibody therapy (L) 419
trinucleotide repeats
experimental studies of toxicity (L) 280
ribozyme-mediated *trans*-splicing (L) 233
role of transglutaminases (L) 187
in schizophrenia (O) 518
triplex DNA (N) 140
tRNA
fimbriation in *E. coli* and (L) 6
trophic factors
transplanted Sertoli cells 471
trophoblast
in pre-eclampsia pathogenesis (O) 286
Ts65Dn mouse
nutritional deficiencies (N) 414
TSC1/TSC2 gene mutations 313
tuberculosis
drug targets and vaccines (M) 104
molecular mechanisms and immunological aspects (M) 330
vaccine development (M) 330
tuberin 313
tuberous sclerosis
genetic basis 313
tumour antigens
in cancer vaccine development (M) 327
heat shock protein–peptide complexes as 478
stimulating cytotoxic T cells 305
tumours *see also* cancer
childhood, role of IGF2 110
immune evasion 63
tumour suppressor genes *see also* individual tumour suppressor genes
BRCA1/BRCA2 263
prostate cancer gene therapy targets 494
serine/threonine kinase (L) 97
in testicular germ cell tumours 404
TSC1/TSC2 313
type III secretion locus (L) 233

U

ulcerative colitis
in IL-2 knockout mice (L) 188
protease inhibitors (N) 461
uncoupling protein homologue, UCPH
in body weight regulation (N) 185
uncoupling proteins, UCP
in body weight regulation (N) 185
in pre-eclampsia pathogenesis (O) 286
urea
therapeutic removal using microencapsulated bacteria 221

uric acid
in multiple sclerosis (L) 144
urine
therapeutic protein production (N) 230

V
vaccines
biological warfare (N) 369
cancer *see* cancer, vaccines
Chlamydia 166
evasion by pneumococci (L) 99
Listeria monocytogenes as vector (M) 240
tuberculosis (M) 104, 330
vascular smooth muscle cells
induced differentiation (N) 110
vectors
brain targeting (B) 421
central nervous system 158
CFTR gene transfer 292
lentiviral (L) 51
non-viral *see also* liposomes, cationic
different strategies (M) 374
DNA–gelatin nanospheres (L) 464
lipid polycation DNA, LPD (N) 323
lipitoids (L) 418
in prostate cancer gene therapy 494
skeletal muscle gene transfer 214
targeting strategies 84
viral *see* viral vectors
velocardiofacial syndrome 350
verteporfin
in photodynamic therapy of psoriasis (N) 416
viral infections
multiple sclerosis and (M) 328
viral vaccines
cancer (M) 327
viral vectors
CFTR gene transfer 292
different strategies (M) 374
production techniques 54
skeletal muscle gene transfer 214
targeting strategies 84
virulence factors
in vivo expression (L) 370
visceroatrial heterotaxia
connexin mutations (M) 192

W
WASP 300
web sites
Genes and disease (N) 509
genomics (L) 240
weight, body
disorders, uncoupling proteins and (N) 185
loss, thyroid hormone analogue (L) 370
Wiskott–Aldrich syndrome
molecular basis 300
wound healing
aging and (M) 466
excess scar formation 19
keratinocyte growth factor 2 therapy 229
nervous system (O) 337

X
X chromosome inactivation (M) 238
Xenomouse
cytokine antibody production (M) 512
xenotransplantation
B-cell tolerization (N) 462
cells and tissues 39
endogenous retroviruses and (L) 280
solid organs (M) 56
X-linked lymphoproliferative disease (L) 510
X-linked mental retardation (L) 511
XX males (L) 143

Y
yeast
Genome Reporter Matrix (N) 48

Z
zeamatin (N) 5